EliteImmune

Executive Summary

EliteImmune is a private San Diego-based biotechnology company leveraging its proprietary CellProbe™ and CellSeq™ platforms to discover and develop antibody-based therapeutics and prophylactics for infectious diseases. Founded in 2015, the company focuses on addressing unmet needs in targeted therapy and prevention of viral and bacterial infections. By utilizing advanced antibody discovery technologies, EliteImmune aims to generate potent, specific, and durable immune responses against high-priority pathogens. The company’s pipeline is early-stage but supported by robust platform capabilities that enable rapid identification of neutralizing antibodies. With a growing emphasis on pandemic preparedness and antimicrobial resistance, EliteImmune is positioned to contribute novel candidates for both acute and chronic infectious diseases. While the company has not disclosed specific financial or clinical milestones, its technology-driven approach and focus on infectious disease align with current market needs. Key risks include early development stage, regulatory hurdles, and competition from larger biopharma. However, successful validation of its platforms could lead to strategic partnerships and accelerated development. The company’s private status limits public visibility, but its science-driven strategy warrants attention from investors interested in infectious disease and antibody-based therapies.

Upcoming Catalysts (preview)

• Q4 2026IND Submission for Lead Antibody Candidate Targeting Respiratory Virus40% success
• Q2 2026Publication of Preclinical Data Demonstrating Broad Neutralization Against Viral Variants70% success
• Q3 2026Announcement of Strategic Partnership with Larger Pharma for Co-Development30% success